NCT07515950Not yet recruiting
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
The REVEAL-BTC Study will analyze 5 biomarkes in samples of participants who in the past 15 year have been diagnosed with any stage of biliary tract cancer. The expression levels of the biomarkers will be correlated with clinical outcomes in the participants, which will lead to better patient stratification that will help guide the use of targeted therapies in the future.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 244 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- MedSIR
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07515950
What you commit to
- Study type: Observational
- Planned participants: 244
- From 1 Jul 2026 to the primary completion date, 31 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unavailability or inadequate quality (e.g., insufficient tumor content, degraded tissue) of archival FFPE tumor tissue samples for the planned immunohistochemical analysis.
- Missing or incomplete basic clinical and/or survival data in the medical record.
Who the study is looking for
- Written informed consent for the use of clinical data and tissue samples is available. (The use of data and samples without consent is only possible if exemption is granted by the corresponding Institutional Review Board - IRB).
- Histologically confirmed diagnosis of biliary tract cancer (including gallbladder carcinoma \[GBC\] or cholangiocarcinoma \[CCA\]), regardless of disease stage.
- Diagnosis must have been established within the last 15 years prior to Study initiation.
- Availability of archival formalin-fixed paraffin-embedded (FFPE) tumor tissue sample, collected prior to Study inclusion at any disease stage (e.g., during surgery or in the advanced setting). For patients with de novo metastatic disease or early stage primary tumors undergoing surgery, the tissue must have been obtained before the initiation of any systemic therapy (e.g. chemotherapy) or radiotherapy. For patients with recurrent disease undergoing a new biopsy, previous treatments are allowed.
- Availability and accessibility of basic clinical information and survival data on medical records.
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.